Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose vs Standard Dose Albumin for PICD Prevention
NCT07917819Phase 4Enrolling by invitation
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 4, randomised trial of albumin (human) in Paracentesis-Induced Circulatory Dysfunction (PICD) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Incidence of Paracentesis-Induced Circulatory Dysfunction at 6 days. Started Oct 2026; status: enrolling by invitation.
02
Drugs
albumin (human)
03
Conditions
Paracentesis-Induced Circulatory Dysfunction (PICD)
Beyond the preview
Go deeper on NCT07917819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917819.